Skip to main content
. 2019 Apr 27;11(5):590. doi: 10.3390/cancers11050590

Figure 6.

Figure 6

PMS treatment preferentially impairs viability of vemurafenib-resistant human malignant melanoma cells with induction of caspase-dependent PARP-cleavage. (A) Differential cytotoxicity of PMS (1 µM; 24 h) was examined in a focused panel of cultured human malignant melanoma cells (A375, A375R (vemurafenib-resistant A375)) and primary melanocytes (HEMa) using flow cytometric analysis (annexin V-PI staining). Numbers in quadrants indicate viable (AV-negative, PI-negative) in percent of total gated cells (mean ± SD, n = 3). (B) Immunoblot-detection of PDGFRβ-upregulation in A375R cells, an established signature molecular change characteristic of vemurafenib-resistant melanoma cells. (C) PMS-induced (1–10 µM, 24 h) PARP1-cleavage, comparing A375 versus A375R malignant melanoma cells.